Importance

Loading Importance Indicators...

Abstract

The invention relates to methods of determining whether a patient responds to a therapeutic treatment of an autoimmune disease, of monitoring the course of an autoimmune disease in a patient, of determining the risk for a relapse of an autoimmune disease in a patient, and of adjusting the dose of a therapeutic drug applied for therapeutic treatment of an autoimmune disease in a patient. Said methods are based on the determination of the level of at least one miRNA in a test sample isolated from the patient. The invention also relates to a method of identifying a compound suitable for the treatment of an autoimmune disease in a patient. Further, the invention relates to the use of a polynucleotide or a polynucleotide set for detecting a miRNA to determine whether a patient responds to a therapeutic treatment of an autoimmune disease, to monitor the course of an autoimmune disease in a patient, to determine the risk of a relapse of an autoimmune disease in a patient, to adjust the dose of a therapeutic drug applied for therapeutic treatment of an autoimmune disease in a patient, and to identify a compound suitable for the treatment of an autoimmune disease in a patient. Furthermore, the invention relates to a kit for determining whether a patient responds to a therapeutic treatment of an autoimmune disease, for monitoring the course of an autoimmune disease in a patient, for determining the risk of a relapse of an autoimmune disease in a patient, for adjusting the dose of a therapeutic drug applied for therapeutic treatment of an autoimmune disease in a patient, or for identifying a compound suitable for the treatment of an autoimmune disease in a patient comprising means for determining the level of at least one miRNA in a test sample isolated from a patient. Said autoimmune disease is not multiple sclerosis (MS).

Loading the Abstract Image...

First Claim